Elevance Health, Inc. (ELV) To Go Ex-Dividend on March 10th

Elevance Health, Inc. (NYSE:ELV) declared a quarterly dividend on Tuesday, January 27th. Shareholders of record on Tuesday, March 10th will be given a dividend of 1.72 per share on Wednesday, March 25th. This represents a c) dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a 0.6% increase from Elevance Health’s previous quarterly dividend of $1.71.

Elevance Health has increased its dividend by an average of 0.2%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. Elevance Health has a payout ratio of 17.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Elevance Health to earn $39.05 per share next year, which means the company should continue to be able to cover its $6.84 annual dividend with an expected future payout ratio of 17.5%.

Elevance Health Trading Up 5.9%

Shares of Elevance Health stock opened at $342.01 on Thursday. The company’s 50-day moving average price is $350.56 and its 200-day moving average price is $328.87. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.71. Elevance Health has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a market cap of $76.01 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 1.66 and a beta of 0.51.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the firm posted $3.84 EPS. Elevance Health’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts expect that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Barclays increased their price objective on Elevance Health from $385.00 to $404.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Guggenheim raised their price target on Elevance Health from $398.00 to $414.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Mizuho set a $413.00 target price on shares of Elevance Health in a research note on Friday, January 9th. Finally, Truist Financial set a $400.00 price target on shares of Elevance Health in a research note on Tuesday, October 14th. Twelve investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average price target of $399.63.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.